MDMA (3,4-methylenedioxy-N-methylamphetamine) for the treatment of tinnitus

This placebo-controlled, double-blind crossover trial (n=40) explores the potential therapeutic effects of a low dose (30-70mg) of MDMA for treating tinnitus.

Registered on ANZCTR with the identifier ACTRN12613000685718, the study involves two phases. Phase 1 assesses the efficacy of one 30 mg dose of MDMA in reducing tinnitus (N = 10), and if ineffective, a 70 mg dose will be tested (N = 10). Phase 2 evaluates the chosen dose’s effects in more patients (N = 20) in a low-sensory environment, with resting-state fMRI scans.

Primary outcomes include the Tinnitus Severity Numeric Scale (TSNS) and the Tinnitus Functional Index (TFI). Eligible participants, aged 18 to 70, must have constant tinnitus perception and good mental/physical health, excluding certain conditions.

Led by Dr Grant Searchfield from the University of Auckland, the trial, approved by the New Zealand Health and Disability Ethics Committees, commenced enrolment on November 19, 2013, and concluded on December 1, 2016. Funding is provided by The University of Auckland Research Faculty.

Compound MDMA Placebo
Country New Zealand
Visit trial

Trial Details



Trial Number

Papers

A proof-of-principle study of the short-term effects of 3,4-methylenedioxymethamphetamine (MDMA) on tinnitus and neural connectivity
This double-blind, randomized, controlled cross-over study (n=13) explores MDMA's (30-70mg) impact on tinnitus through behavioural and rs-fMRI assessments. No notable effects were observed at the lower dose. However, the 70 mg dose significantly reduced tinnitus annoyance and ignore ratings post-administration. Neurophysiological analysis revealed decreased connectivity in emotion and memory-related brain regions (hippocampal and amygdala) and increased connectivity in sensory processing and attention areas (right post-central gyrus, posterior and superior temporal gyrus, thalamus, and frontoparietal network) with MDMA versus placebo.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.